US 2013/0171210 A1 · BISMUTH-THIOLS AS ANTISEPTICS FOR EPITHELIAL TISSUES, ACUTE AND CHRONIC WOUNDS, BACTERIAL BIOFILMS AND OTHER INDICATIONS

Abstract

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.

Claims21

Dependent claims

A method of treating an acute wound, a chronic wound or a wound or epithelial tissue surface that contains bacterial biofilm in a subject, comprising:

administering, to a wound site or to a wound or epithelial tissue surface that contains bacterial biofilm in the subject, a therapeutically effective amount of a topical formulation that comprises (a) a bismuth-thiol (BT) composition that comprises at least one BT compound, and (b) a pharmaceutically acceptable excipient or carrier for topical use.

A method for treating an acute wound, a chronic wound or a wound or epithelial tissue surface that contains bacterial biofilm, comprising:

(a) identifying a bacterial infection in a wound or epithelial tissue surface in a subject as comprising one of (i) gram positive bacteria, (ii) gram negative bacteria, and (iii) both (i) and (ii);
and
(b) treating the wound or epithelial tissue surface by administering a topical formulation that comprises a BT composition which comprises one or more bismuth thiol (BT) compounds to the wound, wherein:
(i) if the bacterial infection comprises gram positive bacteria, then the topical formulation comprises therapeutically effective amounts of at least one BT compound and at least one antibiotic that is rifamycin,
(ii) if the bacterial infection comprises gram negative bacteria, then the topical formulation comprises therapeutically effective amounts of at least one BT compound and amikacin, and
(iii) if the bacterial infection comprises both gram positive and gram negative bacteria, then the topical formulation comprises therapeutically effective amounts of one or a plurality of BT compounds, rifamycin and amikacin.

3 more elements

Dependencies are inferred from the claim text.

Facts

Application

13/782,963Filed 1 Mar 2013

Priority

3 Feb 2009

Published

4 Jul 2013

Term ends

Not estimatedThe source records don’t support an estimate.

Classification20 codes

A61K 31/29
Compounds containing heavy metals: antimony or bismuth compounds
A61K 9/0014
Galenical forms characterised by the site of application: skin, i.e. galenical aspects of topical compositions
A61K 9/145
Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried,…: with…
A61K 31/095
Medicinal preparations containing organic active ingredients: sulfur, selenium, or tellurium compounds, e.g. thiols

Family

Application61/149,593Us provisional application · filed 3 Feb 2009

Application12/699,680Continuation · filed 3 Feb 2010

Application13/782,963Continuation

US 2011/0003001 A1Published application

US 8,389,021 B2Related patent

US 2013/0171210 A1This patent

From the US filing history. Foreign family members aren’t listed.

Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications

Life of this patent

Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications

Life of this patent

Abstract

Claims21